REFERENCES
[1] M. A. Ali, Chronic myeloid leukemia in the era of tyrosine kinase inhibitors: an evolving paradigm of molecularly targeted therapy. Molecular Diagnosis & Therapy, 20 (2016) 315–333.
[2] J. M. Diamond, J.V. Melo, Mechanisms of resistance to BCR-ABL kinase inhibitors. Leukemia & Lymphoma, 52 (2011) 12–22.
[3] T. Lahaye, B. Riehm, U. Berger, P. Paschka, M.C. Müller, S. Kreil, K. Merx, U. Schwindel, C. Schoch, R. Hehlmann, A. Hochhaus, Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer, 103 (2005) 1659–1669.
[4] P. W. Manley, P. Drueckes, G. Fendrich, P. Furet, J. Liebetanz, G. Martiny-Baron, Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 1804 (2010) 445-453.
[5] E. Weisberg, P. Manley, J. Mestan, S. Cowan-Jacob, A. Ray, J. D. Griffin. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. British Journal of Cancer, 94 (2006) 1765-1769.
[6] J. Y. Blay, M. von Mehren, Nilotinib: A novel, selective tyrosine kinase inhibitor. Seminars in Oncology, 38 (2011) S3-S9.
[7] A. R. He, A. S. Goldenberg, Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. Therapeutic Advances in Gastroenterology, 6 (2013) 447-458.
[8] C. H. Takimoto, A. Awada, Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemotherapy and Pharmacology, 61 (2008) 535-548.
[9] S. M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, C. Chen, S. Zhang, P. Vincent, M. McHugh, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research, 64 (2004) e70997109.
[10] J. W. Panka, D. J. Wang, W. Atkins, M. B. Mier, The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase independent apoptosis in melanoma cells. Cancer Research, 66 (2006) 1611–1619.
[11] R. Ivaturi, T. M. Sastry, S. Satyaveni, Development and validation of a stability indicating HPLC method for the determination of nilotinib hydrochloride in bulk and pharmaceutical dosage form. International Journal of Pharmacy and Pharmaceutical Sciences, 8 (2016) 41-48.
[12] A. Barla, K. Buralla, Development and validation of method for the determination of nilotinib by RP-HPLC in bulk and pharmaceutical dosage forms. International Journal of Pharmaceutical Investigation, 3 (2013) 364-367.
[13] Q. Z. Rafeeque, P. S. Dabhade, Development and method validation of RP-HPLC method for simultaneous estimation and forced degradation of sorafenib tosylate in bulk and pharmaceutical dosage form. Innovational Journal of Chemistry, 1 (2016) 63-71.
[14] A. Barla, K. K. Buralla, Development and validation of RP-HPLC method for the estimation of nilotinib in bulk and pharmaceutical dosage form, International Journal of Pharmaceutical Investigation, 10 (2020) 364-367.
[15] A. Rade, K. Patil, T. Thorat, P. Patil and D. Shinde, RP-HPLC method development and validation for the estimation of nilotinib in bulk and tablet dosage form, World Journal of Pharmaceutical Research, 8 (2019) 1286-1294.
[16] W. Talaat, M. M.Y. Kaddah, Validated analytical method for the determination of sorafenib in dosage form and human plasma in presence of it degradation products, International Journal of PharmTech Research, 12 (2019) 08-21.
[17] H. A. Alhazmi, D. Allah Moraya, E. Alahdal, M. Kariri, M. A. Bratty, Z. Rehman, S. A. Javed, Ultrafast monolithic HPLC method for simultaneous quantification of the anticancer agents, imatinib and sorafenib: Application to tablet dosage forms, Tropical Journal of Pharmaceutical Research, 17 (2018) 1127-1134.
[18] I. Khan, Z. Iqbal, A. Khan, M. Hassan, F. Nasir, A. Raza, L. Ahmad, A. Khan, M. A. Mughal, A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib and paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study, Journal of Chromatography B, 1033-1034 (2016) 261-270.
[19] I. Baranowska, B. Kowalski, Using HPLC method with DAD detection for the simultaneous determination of 15 drugs in surface water and wastewater. Polish Journal of Environmental Studies, 20 (2011) 21-28.
[20] ICH Guidelines Q2 (R1), Validation of analytical procedures: Text and methodology, Geneva, 2005.